The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Distinct gene expression patterns identify patients who relapse after neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study.
 
Moritz Johannes Reike
No Relationships to Disclose
 
Daniele Raggi
No Relationships to Disclose
 
Laura Marandino
Research Funding - AstraZeneca
 
Damiano Alfio Patanè
No Relationships to Disclose
 
Emanuele Crupi
No Relationships to Disclose
 
Tiago Costa de Padua
No Relationships to Disclose
 
Peter C. Black
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Biosyent; Bristol-Myers Squibb; EMD Serono; Ferring; Janssen Oncology; Merck; Minogue Medical; miR Scientific; Nonagen Bioscience; Pfizer; Prokarium; Protara Therapeutics; Protara Therapeutics; QED Therapeutics; Roche Canada; Sanofi; Sesen Bio; STIMIT; TerSera; Tolmar; Urogen pharma; Verity Pharmaceuticals
Speakers' Bureau - Bayer; BioSyent; Pfizer; TerSera
Research Funding - iProgen
Patents, Royalties, Other Intellectual Property - 1. PCT/CA2014/000787. Canada. 2014-11-03 Cancer Biomarkers and Classifiers and uses thereof. 2. #61899648 United States. 2013-03-13 Bladder cancer signature.
 
Ewan Gibb
Employment - Decipher Biosciences; Veracyte
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Catalym; Clovis Oncology; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Gilead Sciences; Ipsen; Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Pfizer; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)